Drug Trial Radar · NCT05440708
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
193
Planned (sponsor's estimate)
Start
Mar 23, 2023
Primary completion
May 25, 2027
Study completion Jul 20, 2027
Sponsor
- Lead sponsor
- Tvardi Therapeutics, IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 as a single agent in participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohort A Phase 2 are to assess response, progression, survival, and pharmacokinetics. The primary objectives of Cohorts B and C Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, or unresectable HCC and to determine the MTD and/or RP2D of TTI-101 when used in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C). The primary objectives of Cohorts B and C Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohorts B and C Phase 2 are to assess response, progression, survival, and pharmacokinetics.
Conditions
- Hepatocellular Carcinoma
Interventions
TTI-101Drug
Oral tablet
PembrolizumabDrug
Intravenous (IV) infusion
AtezolizumabDrug
Intravenous (IV) infusion
BevacizumabDrug
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AE)Time frame: Up to approximately 20 months
- Incidence of Serious Adverse Events (SAE)Time frame: Up to approximately 18 months
- Phase 2: Overall Response Rate (ORR) to TTI-101Time frame: Up to approximately 18 months
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
The Kirklin Clinic of University of Alabama Birmingham Hospital
Birmingham, Alabama · Completed
University of California San Diego
La Jolla, California · Completed
Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of California Irvine Medical Center
Orange, California · Recruiting
University of Colorado Hospital - Anschutz Medical Campus
Aurora, Colorado · Recruiting
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Completed
Moffitt Cancer Center
Tampa, Florida · Recruiting
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Completed
Washington University in St. Louis
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center - New York
New York, New York · Recruiting
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio · Completed
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
DHR Health Institute for Research and Development
McAllen, Texas · Recruiting
University of Texas Health Science Center - San Antonio
San Antonio, Texas · Recruiting
Virginia Mason Medical Center
Seattle, Washington · Recruiting
Summit Cancer Centers - North Spokane
Spokane, Washington · Recruiting
Froedtert and Medical College of Wisconsin
Milwaukee, Wisconsin · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.